Comparative Pharmacology
Head-to-head clinical analysis: NAFCILLIN SODIUM versus OMNIPEN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAFCILLIN SODIUM versus OMNIPEN N.
NAFCILLIN SODIUM vs OMNIPEN-N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nafcillin exerts bactericidal activity by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
Omnipen-N (ampicillin sodium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with transpeptidation and resulting in cell lysis.
1-2 g IV every 4 hours; or 1-2 g IM every 4-6 hours.
250-500 mg orally every 6 hours for adults; for severe infections, up to 1 g every 6 hours.
None Documented
None Documented
Approximately 0.5 hour (30 minutes) in adults with normal renal function; prolonged to 1-2 hours in neonates or severe renal impairment. Clinically relevant for dosing every 4-6 hours.
30-60 minutes (normal renal function); prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (30-40% unchanged) and hepatic/biliary elimination. Approximately 10-15% excreted in bile via feces.
Primarily renal (80-90% unchanged via tubular secretion); minor biliary/fecal (<10%).
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic